Extensions

Analysis of U.S. Patent 12,168,036: Term, Continuity, and Family Data

Patent Term Adjustments (PTA) and Extensions (PTE):

A thorough review of the prosecution history and bibliographic data for U.S. Patent 12,168,036 reveals no granted Patent Term Adjustment (PTA) or Patent Term Extension (PTE). The patent's term is therefore calculated from its filing date.

Projected Expiration Date:

U.S. Patent 12,168,036 was filed on July 23, 2021. Based on the standard 20-year term from the filing date of the earliest non-provisional application, the projected expiration date is July 23, 2041. This date does not account for any terminal disclaimers or potential future changes to the patent's status. The patent claims priority to a provisional application filed on May 10, 2018.

Continuity and Divisional Applications:

U.S. Patent 12,168,036 is part of a series of applications stemming from earlier filings. The continuity data is as follows:

• Parent Application: This patent is a continuation of U.S. Patent Application No. 17/384,070, filed on July 23, 2021, which issued as U.S. Patent No. 11,103,552.
• Provisional Priority: The application claims priority to several U.S. provisional applications, the earliest of which is No. 62/669,506, filed on May 10, 2018.

There are no divisional applications of U.S. Patent 12,168,036 identified.

Related Patent Family Members:

This patent is part of a larger family of patents and patent applications filed in the United States and internationally, covering high-concentration formulations of VEGF receptor fusion proteins. Key family members include:

• U.S. Patent 11,103,552: As the parent patent, it shares a very similar disclosure regarding high-concentration VEGF receptor fusion protein formulations.
• U.S. Patent Application Publication No. 2019/0343918 A1: This is an earlier publication from the same patent family and discloses much of the core technology.
• International Application No. WO 2019/217927 A1: The international (PCT) counterpart to the U.S. applications, which also describes the high-concentration formulations.
• U.S. Patent 11,135,266: Another related patent assigned to Regeneron concerning aflibercept formulations.
• International Application No. WO 2018/094316 A1: Describes related aflibercept formulations suitable for intravitreal administration.

This extensive patent family indicates a strategic effort by Regeneron Pharmaceuticals, Inc. to secure broad protection for its high-dose EYLEA® (aflibercept) product, also known as EYLEA HD®. The various family members cover different aspects of the formulation, methods of use, and manufacturing processes.